The VALIDATE network: accelerating vaccine development for tuberculosis, leishmaniasis, melioidosis and leprosy

Established in June 2017, VALIDATE is an international network of researchers working to accelerate vaccine development for four neglected intracellular pathogens that cause significant mortality and morbidity globally: Mycobacterium tuberculosis, Leishmania spp., Burkholderia pseudomallei and Mycob...

Full description

Bibliographic Details
Main Authors: Vermaak, S, Sampson, S, McShane, H
Format: Book section
Language:English
Published: Springer 2023
_version_ 1797112108423315456
author Vermaak, S
Sampson, S
McShane, H
author_facet Vermaak, S
Sampson, S
McShane, H
author_sort Vermaak, S
collection OXFORD
description Established in June 2017, VALIDATE is an international network of researchers working to accelerate vaccine development for four neglected intracellular pathogens that cause significant mortality and morbidity globally: Mycobacterium tuberculosis, Leishmania spp., Burkholderia pseudomallei and Mycobacterium leprae. In 5 years, VALIDATE has grown to have more than 550 members from over 250 institutes across 72 countries and has had several successes and important outputs. This chapter discusses VALIDATE’s origins, achievements and future direction.
first_indexed 2024-03-07T08:19:33Z
format Book section
id oxford-uuid:040bcb5a-ff52-4e0e-ae11-1f53096a30cb
institution University of Oxford
language English
last_indexed 2024-03-07T08:19:33Z
publishDate 2023
publisher Springer
record_format dspace
spelling oxford-uuid:040bcb5a-ff52-4e0e-ae11-1f53096a30cb2024-01-26T11:31:08ZThe VALIDATE network: accelerating vaccine development for tuberculosis, leishmaniasis, melioidosis and leprosyBook sectionhttp://purl.org/coar/resource_type/c_1843uuid:040bcb5a-ff52-4e0e-ae11-1f53096a30cbEnglishSymplectic ElementsSpringer2023Vermaak, SSampson, SMcShane, HEstablished in June 2017, VALIDATE is an international network of researchers working to accelerate vaccine development for four neglected intracellular pathogens that cause significant mortality and morbidity globally: Mycobacterium tuberculosis, Leishmania spp., Burkholderia pseudomallei and Mycobacterium leprae. In 5 years, VALIDATE has grown to have more than 550 members from over 250 institutes across 72 countries and has had several successes and important outputs. This chapter discusses VALIDATE’s origins, achievements and future direction.
spellingShingle Vermaak, S
Sampson, S
McShane, H
The VALIDATE network: accelerating vaccine development for tuberculosis, leishmaniasis, melioidosis and leprosy
title The VALIDATE network: accelerating vaccine development for tuberculosis, leishmaniasis, melioidosis and leprosy
title_full The VALIDATE network: accelerating vaccine development for tuberculosis, leishmaniasis, melioidosis and leprosy
title_fullStr The VALIDATE network: accelerating vaccine development for tuberculosis, leishmaniasis, melioidosis and leprosy
title_full_unstemmed The VALIDATE network: accelerating vaccine development for tuberculosis, leishmaniasis, melioidosis and leprosy
title_short The VALIDATE network: accelerating vaccine development for tuberculosis, leishmaniasis, melioidosis and leprosy
title_sort validate network accelerating vaccine development for tuberculosis leishmaniasis melioidosis and leprosy
work_keys_str_mv AT vermaaks thevalidatenetworkacceleratingvaccinedevelopmentfortuberculosisleishmaniasismelioidosisandleprosy
AT sampsons thevalidatenetworkacceleratingvaccinedevelopmentfortuberculosisleishmaniasismelioidosisandleprosy
AT mcshaneh thevalidatenetworkacceleratingvaccinedevelopmentfortuberculosisleishmaniasismelioidosisandleprosy
AT vermaaks validatenetworkacceleratingvaccinedevelopmentfortuberculosisleishmaniasismelioidosisandleprosy
AT sampsons validatenetworkacceleratingvaccinedevelopmentfortuberculosisleishmaniasismelioidosisandleprosy
AT mcshaneh validatenetworkacceleratingvaccinedevelopmentfortuberculosisleishmaniasismelioidosisandleprosy